Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 3Recruiting 2Completed 2

Sponsor Class

OTHER 6NIH 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Papillary renal cell carcinoma, sporadic 1Hereditary leiomyomatosis and renal cell cancer 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 116Magnetic Resonance Spectroscopy 78Biopsy 69Cyclophosphamide 24pembrolizumab 22Cisplatin 21fludarabine 18Platinum 171,2-diaminocyclohexaneplatinum II citrate 17Taxes 16Paclitaxel 16Carboplatin 16Nivolumab 15Immunoglobulin G 14Disulfides 14X-Rays 13Radiation 13Doxorubicin 12venetoclax 11Radiotherapy 11Gemcitabine 11durvalumab 9cabozantinib 8aldesleukin 8Prednisone 8atezolizumab 7Cytarabine 7olaparib 6lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × NIH × Contrast Media × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT03191149 2026-05-18

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

National Cancer Institute (NCI)

Phase 2 Recruiting
46 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡